[SCHEDULE 13G/A] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock SEC Filing

Rhea-AI Filing Summary

Ong Yee Lung reports beneficial ownership of 20.76% of Cyclacel Pharmaceuticals, Inc.'s common stock class. The filing states he holds an aggregate of 872,000 instruments comprised of 218,000 common shares and three series of warrants — 218,000 Series A, 218,000 Series B and 218,000 Series C — each exercisable into common stock. The filing indicates sole voting and dispositive power over the aggregate amount and affirms the holdings were not acquired to change or influence control of the issuer.

Positive

• Material ownership disclosed: Reporting person holds a significant 20.76% aggregate interest, providing transparency to investors.
• Clear control: Reported sole voting and dispositive power over the disclosed instruments simplifies governance assessment.

Negative

• None.

Insights

Financial Analyst

TL;DR: Disclosure shows a single investor with a material ~20.8% economic interest via shares plus warrants, which could affect dilution and voting dynamics.

The position combines direct equity and option-like warrants in equal tranches, producing concentrated economic exposure while preserving potential future dilution if warrants are exercised. Reporting of sole voting and dispositive power suggests this is an individual, not a passive institution. For investors, the key implications are the current stake size and the potential for increased common shares outstanding if warrants convert; both factors matter to ownership percentages and per-share metrics. The filing contains no statements about plans to influence control.

Corporate Governance Expert

TL;DR: A >20% beneficial owner with sole voting control is materially relevant to governance and shareholder coordination considerations.

This disclosure signals a meaningful single-stockholder concentration with the ability to vote a substantial block unilaterally. The combination of shares and exercisable warrants means the owner's economic and voting interest could change depending on warrant exercise terms. The certification that holdings were not acquired to change control is standard but does not eliminate the practical governance impact of a large, centralized stake. No group affiliations or arrangements are reported.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Cyclacel Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

09/01/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Ong Yee Lung

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 872,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 872,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

872,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

20.76 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: The reporting person's ownership consists of (i) 218,000 shares of common stock, (ii) 218,000 series A warrants to purchase shares of common stock, (iii) 218,000 series B warrants to purchase shares of common stock, and (iv) 218,000 series C warrants to purchase shares of common stock (the series A warrants, series B warrants and series C warrants, collectively, the "Warrants")

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cyclacel Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Item 2.
(a)	Name of person filing: Ong Yee Lung
(b)	Address or principal business office or, if none, residence: 9 JALAN LAWA 3 TAMAN PELANGI INDAH ULU TIRAM 81800 JOHOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 872,000
(b)	Percent of class: 20.76%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 872,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 872,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ong Yee Lung

Signature:	/s/ Ong Yee Lung
Name/Title:	Ong Yee Lung
Date:	09/01/2025

Exhibit Information

Form of Amended and Restated Series A Common Stock Warrant Form of Amended and Restated Series B Common Stock Warrant Form of Amended and Restated Series C Common Stock Warrant sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-2.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-3.htm sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-4.htm

FAQ

How much of Cyclacel (CYCCP) does Ong Yee Lung own?

The filing discloses an aggregate beneficial ownership of 872,000 instruments, representing 20.76% of the class.

What instruments make up Ong Yee Lung's 20.76% stake in Cyclacel (CYCCP)?

The holdings consist of 218,000 common shares plus 218,000 warrants each of Series A, Series B and Series C (totaling 872,000).

Does Ong Yee Lung share voting or disposition power over these Cyclacel (CYCCP) holdings?

No. The filer reports sole voting power and sole dispositive power for the entire aggregate amount.

Was the stake acquired to influence control of Cyclacel (CYCCP)?

The certification in the filing states the securities were not acquired to change or influence control of the issuer.

Is the filing part of a group or disclosed as on behalf of another person?

No. The filing indicates the reporter is not filing as part of a group and no ownership on behalf of another person is reported.